StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

Equities researchers at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a report issued on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Stock Down 1.6 %

Shares of Trevena stock opened at $1.20 on Friday. Trevena has a 52 week low of $1.13 and a 52 week high of $11.25. The stock’s 50-day simple moving average is $1.54 and its 200-day simple moving average is $1.90. The company has a market capitalization of $1.04 million, a price-to-earnings ratio of -0.03 and a beta of 1.05.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.